Impact of adjuvant treatment modalities on the management of patients with stages I–II endometrial stromal sarcoma

Authors:
  • JDJ. Duclos
    J. Duclos
  • ARA. Rey
    A. Rey
  • PDP. Duvillard
    P. Duvillard
  • VLV. Lazar
    V. Lazar
  • CHC. Haie-Meder
    C. Haie-Meder
  • CBC. Balleyguier
    C. Balleyguier
  • CLC. Lhommé
    C. Lhommé
  • PPP. Pautier
    P. Pautier
Publisher website
Google Scholar
Abstract
To explore whether adjuvant treatment options may impact on the prognosis in localized endometrial stromal sarcomas (ESSs; stages I and II). The historical options usually discussed in addition to hysterectomy and bilateral salpingoophorectomy (BSO) are active surveillance, pelvic radiotherapy, chemotherapy and hormonal therapy, alone or in combination. Among 84 consecutive patients treated for ESS at a single referral center, 54 with localized stage disease were identified. Recurrence-free survival and overall survival were estimated and patterns of recurrences described. Univariate and multivariate analyses were carried out. With a median follow-up of 58 months, only one patient had died. None of the 23 patients who had received adjuvant therapy relapsed compared with 13 of 31 patients who had not received any adjuvant therapy. Adjuvant treatments were hormonal therapy (n = 10) and brachytherapy with/without pelvic radiotherapy (n = 13). Almost the majority of relapses were local (92%) and extra-pelvic metastasis was observed in nearly half of the patients (46%). In the multivariate analysis, the major determinants of relapse-free survival were adjuvant treatment, myometrial invasion (P = 0.005) and no BSO (P = 0.005). In this series, adjuvant treatment of localized ESSs was associated with the absence of recurrence.
Funding Information
  • Nadine Midy Foundation

This publication has 22 references indexed in Scilit: